

Sigal Kaplan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4001158/publications.pdf>

Version: 2024-02-01

35
papers

375
citations

1040056

9
h-index

794594

19
g-index

35
all docs

35
docs citations

35
times ranked

480
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK. <i>Current Medical Research and Opinion</i> , 2022, 38, 461-468.	1.9	2
2	Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding. <i>Drug Safety</i> , 2022, 45, 345-357.	3.2	7
3	The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the <sc>United States</sc> medicare database. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	4
4	Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 292-303.	1.9	11
5	Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy. <i>JAMA Internal Medicine</i> , 2021, 181, 275.	5.1	9
6	Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 324-329.	0.7	6
7	Effectiveness of risk minimisation measures for valproate: A cross-sectional survey among physicians in Europe. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 283-291.	1.9	5
8	Real world utilization of 91% day extended levonorgestrel-containing combined oral contraceptives in Europe: a multinational database study. <i>Current Medical Research and Opinion</i> , 2021, 37, 515-522.	1.9	2
9	Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 632674.	3.5	2
10	Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. <i>Contraception</i> , 2021, , .	1.5	4
11	Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance. <i>Drug Safety</i> , 2020, 43, 163-177.	3.2	2
12	Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human Subjects. <i>Drug Research</i> , 2020, 70, 472-477.	1.7	1
13	Effect of age and renal impairment on the pharmacokinetics and safety of trimetazidine: An open-label multiple-dose study. <i>Drug Development Research</i> , 2020, 81, 564-572.	2.9	0
14	Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 219-223.	1.9	4
15	The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany. <i>Current Medical Research and Opinion</i> , 2019, 35, 33-40.	1.9	7
16	Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe. <i>Journal of Drug Assessment</i> , 2019, 8, 70-76.	2.2	1
17	Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe. <i>Clinical Drug Investigation</i> , 2019, 39, 1057-1066.	2.2	4
18	Drug utilization patterns of flupirtine following implementation of risk minimization measures in Germany. <i>Current Medical Research and Opinion</i> , 2019, 35, 1397-1403.	1.9	1

#	ARTICLE	IF	CITATIONS
19	A drug utilization study to evaluate effectiveness of risk minimization measures for trimetazidine in France, Hungary, Romania and Spain. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 400-408.	1.5	0
20	Using patient support programs for pregnancy surveillance: Current paradigm, emerging opportunity. <i>Reproductive Toxicology</i> , 2019, 84, 122-124.	2.9	1
21	Challenges of post-authorization safety studies: Lessons learned and results of a French study of fentanyl buccal tablet. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 457-463.	1.9	4
22	Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1385-1392.	1.9	5
23	Modafinil and the risk of cardiovascular events: Findings from three US claims databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1182-1190.	1.9	10
24	The Prevalence and Trends of Antiviral Medication Use During Pregnancy in the US: A Population-Based Study of 664,297 Deliveries in 2001-2007. <i>Maternal and Child Health Journal</i> , 2014, 18, 64-72.	1.5	8
25	Medication Exposure in Pregnancy Risk Evaluation Program: The Prevalence of Asthma Medication Use During Pregnancy. <i>Maternal and Child Health Journal</i> , 2013, 17, 1611-1621.	1.5	44
26	Antidepressant medication dispensing among montelukast initiators. <i>Journal of Asthma</i> , 2013, 50, 990-995.	1.7	9
27	Prevalence, Trends, and Patterns of Use of Antidiabetic Medications Among Pregnant Women, 2001-2007. <i>Obstetrics and Gynecology</i> , 2013, 121, 106-114.	2.4	22
28	Characterization of Long-Acting Beta ₂ -Adrenergic Agonists Utilization in Asthma Patients. <i>Journal of Asthma</i> , 2012, 49, 1079-1085.	1.7	6
29	Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 158-174.	1.9	42
30	In-hospital management of patients with atrial flutter. <i>American Heart Journal</i> , 2010, 159, 370-376.	2.7	5
31	Blood Pressure and Bone Mineral Density in Premenopausal and Postmenopausal Women. <i>Journal of Women's Health</i> , 2010, 19, 1209-1215.	3.3	3
32	Rhythm Versus Rate Control in the Contemporary Management of Atrial Fibrillation In-Hospital—The views expressed in this report are those of the investigators and do not necessarily represent the views of the FDA. <i>American Journal of Cardiology</i> , 2008, 101, 1134-1141.	1.6	13
33	Duration of therapy with metoclopramide: a prescription claims data study. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 878-881.	1.9	20
34	Reported Adverse Drug Events in Infants and Children Under 2 Years of Age. <i>Pediatrics</i> , 2002, 110, e53-e53.	2.1	111
35	Delayed pregnancy detection and return to fertility with extended levonorgestrel-containing oral contraceptives: A real world setting cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 0, , .	1.9	0